Jinxin Reproductive 2025 Financial Report: Four Major Core Indicators Show Sequential Growth in the Second Half of the Year; 400 Million Yuan Shareholder Return Planned for This Year

Log in to the Sina Finance APP and search for [Information Disclosure] to see more evaluation levels.

Each reporter｜Jin Zhe Each editor｜Wan Qingcheng

Jinxin Fertility (01951.HK) released its 2025 financial report on March 26, which showed an operating revenue of 2.649 billion yuan, adjusted EBITDA of 491 million yuan, and 28,039 egg retrieval cycles. The report indicated a comprehensive recovery in performance in H2 2025, achieving significant growth in four key indicators: “egg retrieval cycles,” “management revenue,” “adjusted EBITDA,” and “net profit.”

At the same time, Jinxin Fertility announced a three-year total shareholder return plan amounting to 50% to 80% of the adjusted EBITDA for the relevant fiscal year, including dividends and share buybacks, with cash dividends accounting for no less than 20% of adjusted EBITDA. Starting from March 26, a share buyback plan of up to 300 million yuan will be executed in the open market over the next 12 months, along with a year-end dividend of 100 million yuan, bringing total shareholder returns to as high as 400 million yuan.

Jinxin Fertility’s CEO Dong Yang stated that the current recovery is not reliant on a single event or a single hospital but is based on a healthier structure, more coordinated platforms, more focused management, and a more efficient organization, maintaining cautious optimism for the future.

On the same day, Jinxin Fertility announced that it would launch a three-year shareholder return plan based on its adjusted free cash flow, achieving a total return of 50% to 80% of the EBITDA for the relevant fiscal year through dividends and share buybacks, with cash dividends accounting for no less than 20% of the annual EBITDA. Jinxin Fertility indicated that despite facing industry challenges and operational difficulties in 2025, the board has decided to recommend a final dividend, amounting to approximately 20% of the group’s EBITDA for 2025. The data shows that the total final dividend for the 2025 fiscal year is approximately 100 million yuan, or 3.7 cents per share.

In addition, the announcement stated that starting from March 26, it would also invest up to 300 million yuan in share buybacks over the next 12 months.

Dong Yang stated: “With the smooth rollout of key projects like the Shenzhen hospital, Jinxin Fertility has crossed the large-scale capital expenditure cycle. We place great importance on the long-term interests of shareholders. This three-year plan not only increases the dividend ratio but also serves as a confidence signal based on the company’s solid financial performance. In the future, we will balance business growth with capital efficiency, sharing the fruits of the group’s high-quality development with investors through a continuous and transparent return system.”

Jinxin Fertility is accelerating the implementation of digitalization and “AI+” in the assisted reproductive industry, gradually completing the transition from single-point applications to a comprehensive medical system-level reconstruction for assisted reproduction, increasingly demonstrating its role in cost reduction and improving industry development standards.

In 2025, Jinxin Fertility’s self-developed IVFormer engine officially entered clinical use, establishing an AI intelligent agent cluster covering the entire process of assisted reproduction, integrating six AI agents for IVF knowledge assistance, file management, treatment plan customization, embryo assessment, pregnancy success rate prediction, and postoperative follow-up guidance, achieving full-cycle intelligent management from initial patient diagnosis to pregnancy confirmation. Currently, this AI intelligent agent has gone abroad and is operational in a hospital in China, having handled over 18,000 patient consultations and clinical assistance cases, with an annual visit volume of over 330,000 in the intelligent operational analysis system. More critically, in the core embryo selection phase, the AI embryo selection model developed based on a time-lapse dynamic culture system has shown a significant increase in clinical pregnancy rates for embryos selected by AI compared to those with the same morphological scores.

Addressing the clinical challenge of male infertility, Jinxin Fertility has jointly developed the AI + microfluidic rare sperm identification and extraction system (SpermSeek) with Harbin Institute of Technology, achieving a sperm detection rate of 66.67% and an accuracy rate of 95.28% in real clinical samples, opening up new treatment pathways for patients with azoospermia and severe oligospermia.

Additionally, the maternal and child AI digital companion system and the “Xiao Nuan” robot, based on the knowledge graph of assisted reproduction and obstetrics and dual medical large models, provide 24-hour medical-grade online services, achieving a deep integration of technological empowerment and humanistic care.

Recently, the Sullivan white paper predicted that Jinxin Fertility’s CAPA-IVM and “3F IVF” solutions launched in 2025 will further enhance the patient experience in assisted reproduction and reduce the medical difficulty of IVF, further building future technological barriers and driving significant growth in the industry.

(This article does not constitute any investment advice. The information disclosed is subject to the company’s announcements. Investors act at their own risk based on this.)

Massive information and precise interpretation are available in the Sina Finance APP.